



US009636329B2

(12) **United States Patent**
Shanmugam et al.

(10) **Patent No.:** **US 9,636,329 B2**
(45) **Date of Patent:** **May 2, 2017**

(54) **METHODS OF TREATING CANCER WITH GLUT INHIBITORS AND OXIDATIVE PHOSPHORYLATION INHIBITORS**

(71) Applicant: **Northwestern University**, Evanston, IL (US)

(72) Inventors: **Malathy Shanmugam**, Lisle, IL (US);
Steven T. Rosen, Chicago, IL (US)

(73) Assignee: **Northwestern University**, Evanston, IL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 347 days.

(21) Appl. No.: **14/073,560**

(22) Filed: **Nov. 6, 2013**

(65) **Prior Publication Data**

US 2014/0142056 A1 May 22, 2014

Related U.S. Application Data

(60) Provisional application No. 61/723,079, filed on Nov. 6, 2012.

(51) **Int. Cl.**

A61K 31/427 (2006.01)

A61K 31/155 (2006.01)

A61K 45/06 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/427** (2013.01); **A61K 31/155** (2013.01); **A61K 45/06** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

8,084,576 B2 * 12/2011 Glover A61K 39/0011
530/350
2008/0176822 A1 * 7/2008 Chen A61K 31/155
514/162
2012/0252749 A1 * 10/2012 Shanmugam G01N 33/57484
514/34

OTHER PUBLICATIONS

Issa, Z. A., Zantout, M. S., & Azar, S. T. (2011). Multiple myeloma and diabetes. *ISRN endocrinology*, 2011.*
Iliopoulos, D., Hirsch, H. A., & Struhl, K. (2011). Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. *Cancer research*, 71(9), 3196-3201.*
Evans, J. L., Honer, C. M., Womelsdorf, B. E., Kaplan, E. L., & Bell, P. A. (1995). The effects of wortmannin, a potent inhibitor of phosphatidylinositol 3-kinase, on insulin-stimulated glucose transport, GLUT4 translocation, antilipolysis, and DNA synthesis. *Cellular signalling*, 7(4), 365-376.*
Bredella et al., "Value of FDG PET in the Assessment of Patients with Multiple Myeloma," *AJR Am J Roentgenol*, 2005, 184(4): 1199-204.

Carr et al., "A Syndrome of Peripheral Lipodystrophy, Hyperlipidaemia and Insulin Resistance in Patients Receiving HIV Protease Inhibitors," *AIDS*, 1998, 12(7): F51-8.

Cheong et al., "Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin is Effective Against a Broad Spectrum of Preclinical Cancer Models," *Mol Cancer Ther*, 2011, 10(12): 2350-62.

Durie et al., "Whole-Body (18)F-FDG PET Identifies High-Risk Myeloma," *J Nucl Med*, 2002, 43(11): 1457-63.

El-Mir et al., "Dimethylbiguanide Inhibits Cell Respiration Via an Indirect Effect Targeted on the Respiratory Chain Complex I," *J Biol Chem*, 2000, 275(1): 223-8.

Evans et al., "Metformin and Reduced Risk of Cancer in Diabetic Patients," *BMJ*, 2005, 330(7503): 1304-5.

Hertel et al., "A Structural Basis for the Acute Effects of HIV Protease Inhibitors on GLUT4 Intrinsic Activity," *J Biol Chem*, 2004, 279(53): 55147-52.

Hresko et al., "HIV Protease Inhibitors Act as Competitive Inhibitors of the Cytoplasmic Glucose Binding Site of GLUTs with Differing Affinities for GLUT1 and GLUT4," *PLoS One*, 2011, 6(9): e25237.

Hsu et al., "Multiple-Dose Pharmacokinetics of Ritonavir in Human Immunodeficiency Virus-Infected Subjects," *Antimicrob Agents Chemother*, 1997, 41(5): 898-905.

Kohli et al., "A Randomized Placebo-Controlled Trial of Metformin for the Treatment of HIV Lipodystrophy," *HIV Med*, 2007, 8(7): 420-6.

McBrayer et al., "Multiple Myeloma Exhibits Novel Dependence on GLUT4, GLUT8, and GLUT11: Implications for Glucose Transporter-Directed Therapy," *Blood*, 2012.

Munshi, "Plasma Cell Disorders: An Historical Perspective," *Hematology*, 2008, 297.

Murata et al., "The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy," *J Biol Chem*, 2000, 275(27): 20251-4.

Owen et al., "Evidence that Metformin Exerts its Anti-Diabetic Effects Through Inhibition of Complex 1 of the Mitochondrial Respiratory Chain," *Biochem J*, 2000, 348 Pt 3: 607-14.

Sahra et al., "Metformin in Cancer Therapy: a New Perspective for an Old Antidiabetic Drug?," *Mol Cancer Ther*, 2010, 9(5): 1092-9.

Vander Heiden et al., "Growth Factors Can Influence Cell Growth and Survival Through Effects on Glucose Metabolism," *Mol Cell Biol*, 2001, 21(17): 5899-912.

(Continued)

Primary Examiner — Shaojia Anna Jiang

Assistant Examiner — Dale R Miller

(74) *Attorney, Agent, or Firm* — Andrus Intellectual Property Law, LLP

(57)

ABSTRACT

Disclosed herein are methods of treating, diagnosing, and prognosing GLUT-dependent cancers and OXPHOS-dependent cancers. In some embodiments, the methods comprise administering to a patient in need thereof a GLUT inhibitor and/or an OXPHOS inhibitor. The inhibitors may be administered before, concurrently, or after one another. Suitable GLUT-dependent cancers may include a GLUT4-dependent cancer, a GLUT8-dependent cancer, and a GLUT11-dependent cancer. Suitable GLUT inhibitors may include a GLUT4 inhibitor, a GLUT8 inhibitor, and a GLUT11 inhibitor. Suitable OXPHOS-dependent cancers may include mitochondrial OXPHOS-dependent cancers, including cancers that have developed resistance to treatment with a GLUT-inhibitor.

13 Claims, 25 Drawing Sheets